Foghorn Therapeutics Inc. (FHTX) vs Genelux Corporation (GNLX)
A side-by-side comparison of Foghorn Therapeutics Inc. and Genelux Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FHTX
Foghorn Therapeutics Inc.
$1.91HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
GNLX
Genelux Corporation
$2.55HealthcareDelayed quote: Oct 6, 2026, 10:38 AM EDT
Total return — FHTX vs GNLX
growth of $100 · dividends reinvested · last 4yFHTX -76.4% (-30.3%/yr)GNLX -57.7% (-19.4%/yr)GNLX compounded faster over this window
FHTX GNLX
FHTX vs GNLX: by the numbers
- •GNLX is the larger company ($114M vs $112M market cap).
- •Both run net losses; FHTX's is the smaller (-175.78% vs -422412.50% net margin).
Metrics side by side
Valuation
| Metric | FHTX | GNLX |
|---|---|---|
| P/S ratio | 3.05 | 14292.88 |
| P/B ratio | N/A | 7.10 |
Profitability
| Metric | FHTX | GNLX |
|---|---|---|
| Gross margin | 89.22% | -7075.00% |
| Operating margin | -265.64% | -415175.00% |
| Net margin | -175.78% | -422412.50% |
| ROE | N/A | -209.73% |
| ROIC | -44.81% | -192.18% |
Growth (annualized)
| Metric | FHTX | GNLX |
|---|---|---|
| Revenue CAGR (5Y) | 105.83% | N/A |
| Total return CAGR (5Y) | -31.87% | N/A |
Go deeper
Dig into the metrics
Foghorn Therapeutics ROEGenelux ROEFoghorn Therapeutics operating marginGenelux operating marginFoghorn Therapeutics revenue growthGenelux revenue growthFoghorn Therapeutics free cash flowGenelux free cash flow
Foghorn Therapeutics & Genelux appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.